Cyclosporine and psoriasis: 2008 National Psoriasis Foundation* Consensus Conference

Journal of the American Academy of Dermatology

Volumn 62, Issue 5, 2010, Pages 838-853

  Rosmarin, David M ^a   Lebwohl, Mark ^b   Elewski, Boni E ^c   Gottlieb, Alice B ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

cyclosporine; psoriasis; psoriatic arthritis; review; therapy

Indexed keywords

AMPHOTERICIN B; CALCIPOTRIOL; CAPTOPRIL; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; CYCLOSPORIN; DICLOFENAC; DITHRANOL; DROSPIRENONE; GENTAMICIN; INDOMETACIN; KETOCONAZOLE; LISINOPRIL; MELPHALAN; METHOTREXATE; NAPROXEN; SPIRONOLACTONE; SULINDAC; TACROLIMUS; TOBRAMYCIN; VANCOMYCIN;

ABDOMINAL DISCOMFORT; ABNORMAL VISION; ACNE; BLEEDING DISORDER; BLOOD CLOTTING DISORDER; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRY SKIN; FLU LIKE SYNDROME; FOLLICULITIS; GINGIVA BLEEDING; HIRSUTISM; HOT FLUSH; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPERTRIGLYCERIDEMIA; INCREASED APPETITE; INSOMNIA; KERATOSIS; KIDNEY DISEASE; LETHARGY; MUSCULOSKELETAL PAIN; NAUSEA AND VOMITING; NEPHROTOXICITY; NERVOUSNESS; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PUVA; REVIEW; SIDE EFFECT; SKIN CANCER; THORAX PAIN; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; URINARY FREQUENCY; VERTIGO; VIRUS INFECTION;

ADOLESCENT; ADULT; ANIMALS; CHILD; CYCLOSPORINE; DRUG INTERACTIONS; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; HYPERTENSION; KIDNEY DISEASES; PREGNANCY; PSORIASIS;

EID: 77950596138     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.05.017     Document Type: Review

References (117)

1. Borel J.F., Feurer C., Gubler H.U., and Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 43 (1994) 179-186
2. Mueller W., and Herrmann B. Cyclosporin A for psoriasis. N Engl J Med 301 (1979) 555
3. Lebwohl M., Ellis C., Gottlieb A., Koo J., Krueger G., Linden K., et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 39 (1998) 464-475
4. Griffiths C.E., Dubertret L., Ellis C.N., Finlay A.Y., Finzi A.F., Ho V.C., et al. Cyclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 150 Suppl (2004) 11-23
5. Marsland A.M., and Griffiths C.E. The macrolide immunosuppressants in dermatology: mechanisms of action. Eur J Dermatol 12 (2002) 618-622
6. Gottlieb A.B., Grossman R.M., Khandke L., Carter D.M., Sehgal P.B., Fu S.M., et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol 98 (1992) 302-309
7. Prens E.P., van Joost T., Hegmans J.P., Hooft-Benne K., Ysselmuiden O.E., and Benner R. Effects of cyclosporine on cytokines and cytokine receptors in psoriasis. J Am Acad Dermatol 33 (1995) 947-953
8. Horrocks C., Duncan J.I., Oliver A.M., and Thomson A.W. Adhesion molecule expression in psoriatic skin lesions and the influence of cyclosporin A. Clin Exp Immunol 84 (1991) 157-162
9. Haider A.S., Lowes M.A., Suarez-Farinas M., Zaba L.C., Cardinale I., Khatcherian A., et al. Identification of cellular pathways of "type 1," Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol 180 (2008) 1913-1920
10. Alvarez-Arroyo M.V., Yague S., Wenger R.M., Pereira D.S., Jimenez S., Gonzalez-Pacheco F.R., et al. Cyclophilin-mediated pathways in the effect of cyclosporin A on endothelial cells: role of vascular endothelial growth factor. Circ Res 91 (2002) 202-209
11. Griffiths C.E., Clark C.M., Chalmers R.J., Li Wan Po A., and Williams H.C. A systematic review of treatments for severe psoriasis. Health Technol Assess 4 (2000) 1-125
12. Ellis C.N., Fradin M.S., Messana J.M., Brown M.D., Siegel M.T., Hartley A.H., et al. Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial. N Engl J Med 324 (1991) 277-284
13. Berth-Jones J., Henderson C.A., Munro C.S., Rogers S., Chalmers R.J., Boffa M.J., et al. Treatment of psoriasis with intermittent short course cyclosporin (Neoral): a multicenter study. Br J Dermatol 136 (1997) 527-530
14. Ho V.C., Griffiths C.E., Albrecht G., Vanaclocha F., Leon-Dorantes G., Atakan N., et al. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicenter, randomized study: the PISCES study group. Br J Dermatol 141 (1999) 283-291
15. Ho V.C., Griffiths C.E., Berth-Jones J., Papp K.A., Vanaclocha F., Dauden E., et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 44 (2001) 643-651
16. Faerber L., Braeutigam M., Weidinger G., Mrowietz U., Christophers E., Schulze H.J., et al. Cyclosporine in severe psoriasis: results of a meta-analysis in 579 patients. Am J Clin Dermatol 2 (2001) 41-47
17. Nast A., Kopp I., Augustin M., Banditt K.B., Boehncke W.H., Follmann M., et al. German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 299 (2007) 111-138
18. Meinardi M.M., Westerhof W., and Bos J.D. Generalized pustular psoriasis (von Zumbusch) responding to cyclosporin A. Br J Dermatol 116 (1987) 269-270
19. Studio Italiano Multicentrico nella Psoriasi (SIMPSO). Management of erythrodermic psoriasis with low-dose cyclosporin. Dermatology 187 Suppl (1993) 30-37
20. Syuto T., Abe M., Ishibuchi H., and Ishikawa O. Successful treatment of psoriatic nails with low-dose cyclosporine administration. Eur J Dermatol 17 (2007) 248-249
21. Mahrle G., Schulze H.J., Farber L., Weidinger G., and Steigleder G.K. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 32 (1995) 78-88
22. Heydendael V.M., Spuls P.I., Opmeer B.C., de Borgie C.A., Reitsma J.B., Goldschmidt W.F., et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 349 (2003) 658-665
23. Flytstrom I., Stenberg B., Svensson A., and Bergbrant I.M. Methotrexate vs cyclosporin in psoriasis: effectiveness, quality of life and safety; a randomized controlled trial. Br J Dermatol 158 (2008) 116-121
24. Mrowietz U., Farber L., Henneicke-von Zepelin H.H., Bachmann H., Welzel D., and Christophers E. Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: results of a multicenter study; German multicenter study. J Am Acad Dermatol 33 (1995) 470-475
25. Shupack J., Abel E., Bauer E., Brown M., Drake L., Freinkel R., et al. Cyclosporine as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol 36 (1997) 423-432
26. Mahrle G., Schulze H.J., Brautigam M., Mischer P., Schopf R., Jung E.G., et al. Anti-inflammatory efficacy of low-dose cyclosporin A in psoriatic arthritis: a prospective multicenter study. Br J Dermatol 135 (1996) 752-757
27. Salvarani C., Macchioni P., Olivieri I., Marchesoni A., Cutolo M., Ferraccioli G., et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 28 (2001) 2274-2282
28. Touw C.R., Hakkaart-Van Roijen L., Verboom P., Paul C., Rutten F.F., and Finlay A.Y. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 144 (2001) 967-972
29. Powles A.V., Hardman C.M., Porter W.M., Cook T., Hulme B., and Fry L. Renal function after 10 years' treatment with cyclosporin for psoriasis. Br J Dermatol 138 (1998) 443-449
30. Lowe N.J., Wieder J.M., Rosenbach A., Johnson K., Kunkel R., Bainbridge C., et al. Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol 35 (1996) 710-719
31. Paul C.F., Ho V.C., McGeown C., Christophers E., Schmidtmann B., Guillaume J.C., et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 120 (2003) 211-216
32. Doherty S.D., Van Voorhees A., Lebwohl M.G., Korman N.J., Young M.S., Hsu S., et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 59 (2008) 209-217
33. Marcil I., and Stern R.S. Squamous-cell cancer of the skin in patients given PUVA and cyclosporin: nested cohort crossover study. Lancet 358 (2001) 1042-1045
34. Neoral [package insert] (2005), Novartis Pharmaceuticals Corp, East Hanover, NJ
35. Cattaneo D., Perico N., and Remuzzi G. Generic cyclosporine formulations: more open questions than answers. Transpl Int 18 (2005) 371-378
36. Christians U., First M.R., and Benet L.Z. Recommendations for bioequivalence testing of cyclosporine generics revisited. Ther Drug Monit 22 (2000) 330-345
37. Zachariae H., Abrams B., Bleehen S.S., Brautigam M., Burrows D., Ettelt M.J., et al. Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicenter assessment of safety and tolerability. Dermatology 196 (1998) 231-236
38. Berth-Jones J. The use of cyclosporin in psoriasis. J Dermatolog Treat 16 (2005) 258-277
39. Heydendael V.M., Spuls P.I., Ten Berge I.J., Opmeer B.C., Bos J.D., and de Rie M.A. Cyclosporin trough levels: is monitoring necessary during short-term treatment in psoriasis? A systematic review and clinical data on trough levels. Br J Dermatol 147 (2002) 122-129
40. Hashizume H., Ito T., Yagi H., Takigawa M., Kageyama H., Furukawa F., et al. Efficacy and safety of preprandial versus postprandial administration of low-dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris. J Dermatol 34 (2007) 430-434
41. Vakeva L., Reitamo S., Pukkala E., Sarna S., and Ranki A. Long-term follow-up of cancer risk in patients treated with short-term cyclosporine. Acta Derm Venereol 88 (2008) 117-120
42. Versluis D.J., Beyer W.E., Masurel N., Wenting G.J., and Weimar W. Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine. Transplantation 42 (1986) 376-379
43. Grekas D., Alivanis P., Kiriazopoulou V., Dioudis C., Sioulis A., Derveniotis V., et al. Influenza vaccination on renal transplant patients is safe and serologically effective. Int J Clin Pharmacol Ther Toxicol 31 (1993) 553-556
44. Soesman N.M., Rimmelzwaan G.F., Nieuwkoop N.J., Beyer W.E., Tilanus H.W., Kemmeren M.H., et al. Efficacy of influenza vaccination in adult liver transplant recipients. J Med Virol 61 (2000) 85-93
45. Grossman R.M., Delaney R.J., Brinton E.A., Carter D.M., and Gottlieb A.B. Hypertriglyceridemia in patients with psoriasis treated with cyclosporine. J Am Acad Dermatol 25 (1991) 648-651
46. Stiller M.J., Pak G.H., Kenny C., Jondreau L., Davis I., Wachsman S., et al. Elevation of fasting serum lipids in patients treated with low-dose cyclosporine for severe plaque-type psoriasis: an assessment of clinical significance when viewed as a risk factor for cardiovascular disease. J Am Acad Dermatol 27 (1992) 434-438
47. Taler S.J., Textor S.C., Canzanello V.J., and Schwartz L. Cyclosporin-induced hypertension: incidence, pathogenesis and management. Drug Saf 20 (1999) 437-449
48. Markham T., Watson A., and Rogers S. Adverse effects with long-term cyclosporin for severe psoriasis. Clin Exp Dermatol 27 (2002) 111-114
49. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
50. Paul M.D., Parfrey P.S., Smart M., and Gault H. The effect of ethanol on serum cyclosporine A levels in renal transplant recipients. Am J Kidney Dis 10 (1987) 133-135
51. Menter M.A., See J.A., Amend W.J., Ellis C.N., Krueger G.G., Lebwohl M., et al. Proceedings of the psoriasis combination and rotation therapy conference. Deer Valley, Utah, Oct. 7-9, 1994. J Am Acad Dermatol 34 (1996) 315-321
52. Griffiths C.E., Powles A.V., Baker B.S., Fry L., and Valdimarsson H. Combination of cyclosporine A and topical corticosteroid in the treatment of psoriasis. Transplant Proc 20 Suppl (1988) 50-52
53. Katz H.I. Combined topical calcipotriene ointment 0.005% and various systemic therapies in the treatment of plaque-type psoriasis vulgaris: review of the literature and results of a survey sent to 100 dermatologists. J Am Acad Dermatol 37 Suppl (1997) S62-S68
54. Grossman R.M., Thivolet J., Claudy A., Souteyrand P., Guilhou J.J., Thomas P., et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol 31 (1994) 68-74
55. Ashcroft D.M., Li Wan Po A., Williams H.C., and Griffiths C.E. Combination regimens of topical calcipotriene in chronic plaque psoriasis: systematic review of efficacy and tolerability. Arch Dermatol 136 (2000) 1536-1543
56. Gottlieb S.L., Heftler N.S., Gilleaudeau P., Johnson R., Vallat V.P., Wolfe J., et al. Short-contact anthralin treatment augments therapeutic efficacy of cyclosporine in psoriasis: a clinical and pathologic study. J Am Acad Dermatol 33 (1995) 637-645
57. Abel E.A. Phototherapy: Uvb and PUVA. Cutis 64 (1999) 339-342
58. van de Kerkhof P.C. Therapeutic strategies: rotational therapy and combinations. Clin Exp Dermatol 26 (2001) 356-361
59. Hunt M.J., Lee S.H., Salisbury E.L., Wills E.J., and Armati R. Generalized pustular psoriasis responsive to PUVA and oral cyclosporin therapy. Australas J Dermatol 38 (1997) 199-201
60. Momtaz T.K., and Fitzpatrick T.B. Modifications of PUVA. Dermatol Clin 13 (1995) 867-873
61. Korstanje M.J., and Hulsmans R.F. Combination therapy cyclosporin A-PUVA in psoriasis. Acta Derm Venereol 70 (1990) 89-90
62. Petzelbauer P., Honigsmann H., Langer K., Anegg B., Strohal R., Tanew A., et al. Cyclosporin A in combination with photochemotherapy (PUVA) in the treatment of psoriasis. Br J Dermatol 123 (1990) 641-647
63. van de Kerkhof P.C., and de Rooij M.J. Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporin treatment: response to long-term acitretin maintenance. Br J Dermatol 136 (1997) 275-278
64. Lebwohl M. Combining the new biologic agents with our current psoriasis armamentarium. J Am Acad Dermatol 49 Suppl (2003) S118-S124
65. Maryles S., Rozenblit M., and Lebwohl M. Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. J Dermatolog Treat 14 Suppl (2003) 7-16
66. Korstanje M.J., van Breda Vriesman C.J., and van de Staak W.J. Cyclosporine and methotrexate: a dangerous combination. J Am Acad Dermatol 23 (1990) 320-321
67. Fraser A.D., van Kuijk A.W., Westhovens R., Karim Z., Wakefield R., Gerards A.H., et al. A randomized, double blind, placebo controlled, multicenter trial of combination therapy with methotrexate plus cyclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 64 (2005) 859-864
68. Aydin F., Canturk T., Senturk N., and Turanli A.Y. Methotrexate and cyclosporin combination for the treatment of severe psoriasis. Clin Exp Dermatol 31 (2006) 520-524
69. Clark C.M., Kirby B., Morris A.D., Davison S., Zaki I., Emerson R., et al. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol 141 (1999) 279-282
70. Gul U., Gonul M., Kilic A., Erdem R., Cakmak S.K., and Gunduz H. Treatment of psoriatic arthritis with etanercept, methotrexate, and cyclosporin A. Clin Ther 28 (2006) 251-254
71. Wong K.C., and Georgouras K. Low dose cyclosporin A and methotrexate in the treatment of psoriasis. Acta Derm Venereol 79 (1999) 87
72. Mazzanti G., Coloni L., De Sabbata G., and Paladini G. Methotrexate and cyclosporin combined therapy in severe psoriatic arthritis: a pilot study. Acta Derm Venereol Suppl (Stockh) 186 (1994) 116-117
73. Koo J. Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad Dermatol 41 Suppl (1999) S25-S28
74. Roenigk Jr. H.H. Acitretin combination therapy. J Am Acad Dermatol 41 Suppl (1999) S18-S21
75. Kuijpers A.L., van Dooren-Greebe J.V., and van de Kerkhof P.C. Failure of combination therapy with acitretin and cyclosporin A in 3 patients with erythrodermic psoriasis. Dermatology 194 (1997) 88-90
76. Tuxen A.J., Yong M.K., Street A.C., and Dolianitis C. Disseminated cryptococcal infection in a patient with severe psoriasis treated with efalizumab, methotrexate and cyclosporin. Br J Dermatol 157 (2007) 1067-1068
77. Cather J.C., and Menter A. Combining traditional agents and biologics for the treatment of psoriasis. Semin Cutan Med Surg 24 (2005) 37-45
78. Stebbins W.G., and Lebwohl M.G. Biologics in combination with nonbiologics: efficacy and safety. Dermatol Ther 17 (2004) 432-440
79. Krueger G.G., Gottlieb A.B., Sterry W., Korman N., and Van De Kerkhof P. A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis. J Dermatolog Treat 19 (2008) 146-155
80. Langewouters A.M., Van Erp P.E., De Jong E.M., and Van De Kerkhof P.C. The added therapeutic efficacy and safety of alefacept in combination with other (systemic) anti-psoriatics in refractory psoriasis. J Dermatolog Treat 17 (2006) 362-369
81. Ricotti C., and Kerdel F.A. Subacute annular generalized pustular psoriasis treated with etanercept and cyclosporine combination. J Drugs Dermatol 6 (2007) 738-740
82. Strober B.E., and Clarke S. Etanercept for the treatment of psoriasis: combination therapy with other modalities. J Drugs Dermatol 3 (2004) 270-272
83. Menter A., Hamilton T.K., Toth D.P., Leung H.M., Wetherill G., Hennessey B., et al. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, phase IIIb study. Int J Dermatol 46 (2007) 637-648
84. Dadlani C., and Orlow S.J. Treatment of children and adolescents with methotrexate, cyclosporine, and etanercept: review of the dermatologic and rheumatologic literature. J Am Acad Dermatol 52 (2005) 316-340
85. Ruperto N., Ravelli A., Castell E., Gerloni V., Haefner R., Malattia C., et al. Cyclosporine A in juvenile idiopathic arthritis: results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin Exp Rheumatol 24 (2006) 599-605
86. Pistoia V., Buoncompagni A., Scribanis R., Fasce L., Alpigiani G., Cordone G., et al. Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis: results of a preliminary study. Clin Exp Rheumatol 11 (1993) 203-208
87. Kilic S.S., Hacimustafaoglu M., Celebi S., Karadeniz A., and Ildirim I. Low dose cyclosporin A treatment in generalized pustular psoriasis. Pediatr Dermatol 18 (2001) 246-248
88. Kim H.S., Kim G.M., and Kim S.Y. Two-stage therapy for childhood generalized pustular psoriasis: low-dose cyclosporin for induction and maintenance with acitretin/narrowband ultraviolet B phototherapy. Pediatr Dermatol 23 (2006) 306-308
89. Pedreira C.C., King E., Jones G., Moore E., Zacharin M., Varigos G., et al. Oral cyclosporin plus topical corticosteroid therapy diminishes bone mass in children with eczema. Pediatr Dermatol 24 (2007) 613-620
90. Fisher E.J., Berk D.R., Greene R.E., Shaner P., Sweet S.C., and Mallory S.B. Preferred methods of excess hair removal in pediatric patients with lung transplantation. J Am Acad Dermatol 55 (2006) 320-323
91. Ghanem M.E., El-Baghdadi L.A., Badawy A.M., Bakr M.A., Sobhe M.A., and Ghoneim M.A. Pregnancy outcome after renal allograft transplantation: 15 years experience. Eur J Obstet Gynecol Reprod Biol 121 (2005) 178-181
92. Oliveira L.G., Sass N., Sato J.L., Ozaki K.S., and Medina Pestana J.O. Pregnancy after renal transplantation-a five-year single-center experience. Clin Transplant 21 (2007) 301-304
93. Naqvi R., Noor H., Ambareen S., Khan H., Haider A., Jafri N., et al. Outcome of pregnancy in renal allograft recipients: SIUT experience. Transplant Proc 38 (2006) 2001-2002
94. Basri N., Al-Ghamdi, Shaheen F., Hejaili Flaiw Qureshi J., Al-Khader A., et al. Pregnancies in renal transplant recipients-with a focus on babies. Ann Transplant 9 (2004) 65-67
95. Christopher V., Al-Chalabi T., Richardson P.D., Muiesan P., Rela M., Heaton N.D., et al. Pregnancy outcome after liver transplantation: a single-center experience of 71 pregnancies in 45 recipients. Liver Transpl 12 (2006) 1138-1143
96. Angelberger S., Reinisch W., and Dejaco C. Prevention of abortion by cyclosporin treatment of fulminant ulcerative colitis during pregnancy. Gut 55 (2006) 1364-1365
97. Reddy D., Murphy S.J., Kane S.V., Present D.H., and Kornbluth A.A. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol 103 (2008) 1203-1209
98. Ostensen M., Lockshin M., Doria A., Valesini G., Meroni P., Gordon C., et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs (2008), (Oxford), Rheumatology 47(Suppl):iii28-31
99. Ghafari A., and Sanadgol H. Pregnancy after renal transplantation: ten-year single-center experience. Transplant Proc 40 (2008) 251-252
100. Biggioggero M., Borghi M.O., Gerosa M., Trespidi L., Cimaz R., and Meroni P.I. Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants. Lupus 16 (2007) 651-656
101. Meregalli E., Biggioggero M., Borghi O., Meroni P., and Cimaz R. In vivo effects of maternal immunosuppression during pregnancy on the immune function of newborn infants. Arh Hig Rada Toksikol 56 (2005) 151-156
102. Tendron-Franzin A., Gouyon J.B., Guignard J.P., Decramer S., Justrabo E., Gilbert T., et al. Long-term effects of in utero exposure to cyclosporin A on renal function in the rabbit. J Am Soc Nephrol 15 (2004) 2687-2693
103. Cochat P., Decramer S., Robert-Gnansia E., Dubourg L., and Audra P. Renal outcome of children exposed to cyclosporine in utero. Transplant Proc 36 Suppl (2004) 208S-210S
104. Sivaraman P. Management of pregnancy in transplant recipients. Transplant Proc 36 (2004) 1999-2000
105. Gengraf [package insert]. Physicians' Desk Reference. 61st ed. (2007), Thomson PDR, Motvale, NJ
106. Raychaudhuri S.P., Navare T., Gross J., and Raychaudhuri S.K. Clinical course of psoriasis during pregnancy. Int J Dermatol 42 (2003) 518-520
107. Everson G.T. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 8 Suppl (2002) S19-S27
108. Oton E., Barcena R., Castillo M., Barreales M., Blesa C., Moreno-Planas J.M., et al. Hepatitis C virus recurrence after liver transplantation: influence of immunosuppressive regimens on viral load and liver histology. Transplant Proc 38 (2006) 2499-2501
109. Imafuku S., Tashiro A., and Furue M. Cyclosporin treatment of psoriasis in a patient with chronic hepatitis C. Br J Dermatol 156 (2007) 1367-1369
110. Kamar N., Selves J., Sandres-Saune K., Durand D., Izopet J., and Rostaing L. Does cyclosporine have a beneficial effect on the course of chronic hepatitis C infection after renal transplantation?. Transplant Proc 38 (2006) 1329-1332
111. Miura H., Itoh Y., Matsumoto Y., Tani M., Tanabe N., Isonokami M., et al. Long-term administration of cyclosporin A to HCV-antibody-positive patients with dermatologic diseases. Int J Dermatol 38 (1999) 310-314
112. Tourne L., Durez P., Van Vooren J.P., Farber C.M., Liesnard C., Heenen M., et al. Alleviation of HIV-associated psoriasis and psoriatic arthritis with cyclosporine. J Am Acad Dermatol 37 (1997) 501-502
113. Harper J.I., Berth-Jones J., Camp R.D., Dillon M.J., Finlay A.Y., Holden C.A., et al. Cyclosporin for atopic dermatitis in children. Dermatology 203 (2001) 3-6
114. Schmitt J., Schmitt N., and Meurer M. Cyclosporin in the treatment of patients with atopic eczema-a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 21 (2007) 606-619
115. Bar Oz B., Hackman R., Einarson T., and Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 71 (2001) 1051-1055
116. Armenti V.T., Ahlswede K.M., Ahlswede B.A., Jarrell B.E., Moritz M.J., and Burke J.F. National transplantation pregnancy registry-outcomes of 154 pregnancies in cyclosporine-treated female kidney transplant recipients. Transplantation 57 (1994) 502-506
117. Lewkowicz D., and Gottlieb A.B. Pediatric psoriasis and psoriatic arthritis. Dermatol Ther 17 (2004) 364-375